We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




WHO Warning: Rapid Tests Misdiagnose Many Cases of P. falciparum Malaria in Africa

By LabMedica International staff writers
Posted on 05 Oct 2021
A pair of mutations, which result in deletion of the Plasmodium falciparum histidine-rich protein 2 (HRP2), render the malaria parasite invisible to the most commonly used rapid diagnostic tests.

In Africa, most rapid diagnostic tests (RDTs) for falciparum malaria recognize histidine-rich protein 2 antigen. Plasmodium falciparum parasites lacking histidine-rich protein 2 (pfhrp2) and 3 (pfhrp3) genes escape detection by these RDTs. More...


HRP2 is a histidine- and alanine-rich, water-soluble protein, which is localized in several cell compartments including the parasite cytoplasm. The antigen is expressed only by P. falciparum trophozoites. A substantial amount of the HRP2 is secreted by the parasite into the host bloodstream, and the antigen can be detected in erythrocytes, serum, plasma, cerebrospinal fluid, and even urine as a secreted water-soluble protein.

Investigators at the University of North Carolina School of Medicine (Chapel Hill, USA) used several advanced genomic tools to determine the extent of HRP2 deletions expressed by P. falciparum in Africa. Specifically, they analyzed blood samples from a cohort of 12,572 participants enrolled in a prospective, cross-sectional survey along Ethiopia’s borders with Eritrea, Sudan, and South Sudan using RDTs, multiple PCR assays, an ultrasensitive bead-based immunoassay for antigen detection, whole-genome sequencing (WGS) and/or molecular inversion probe (MIP) deep sequencing.

Results indicated that histidine-rich protein 2-based RDTs would miss approximately 9.7% of P. falciparum malaria cases owing to deletion of the pfhrp2 gene.

“This is a serious problem for malaria control efforts and a reminder that pathogens are very capable of adapting to survive,” said senior author Dr. Jonathan B. Parr, assistant professor of infectious diseases at the University of North Carolina School of Medicine. “Surveillance across the Horn of Africa and alternative malaria diagnostic approaches in affected regions are urgently needed. Our work indicates that prhrp3 deletions have arisen independently multiple times over the course of years. “We also found signs that RDT-based testing and treatment are driving a recent rise in pfhrp2 deletion mutation prevalence, allowing parasites to escape detection.”

The World Health Organization (WHO) now recommends that all malaria endemic countries start and maintain surveillance for pfhrp2/3 deletions and respond appropriately when they are confirmed, in order to prevent unnecessary morbidity and deaths and to safeguard inroads that have been made towards malaria elimination, particularly in sub-Saharan Africa.

The malaria RDT paper was published in the September 27, 2021, online edition of the journal Nature Microbiology.

Related Links:
University of North Carolina School of Medicine


Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
New
Silver Member
Quality Control Material
Multichem ID-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.